Two Drugs Started for One Prostate That No Longer Exists the Same Way
A surgery resolved his obstruction three months ago. Nobody has revisited the two medications started before it, and one of them may be the actual reason he's dizzy every time he stands up.
C.L., 70, had circled this month's calendar for a return to the sixty-mile group rides he'd given up over the past two years as his prostate symptoms worsened — he underwent TURP three months ago specifically so he could get back on his bike without planning routes around gas station bathrooms. The surgery worked: his AUA symptom score has fallen from 24 before surgery to 4 today, and his stream, by his own description, is "better than it's been in a decade." What brought him in today wasn't his prostate at all — it was a new antihypertensive his cardiologist started six weeks ago, which he suspected was causing the lightheadedness he's had on standing most mornings since.
Reviewing his medication list, nobody has actually revisited his tamsulosin and finasteride since he started them nine months ago, well before surgery was even scheduled. Both have simply continued through the perioperative period and into recovery without anyone stopping to ask whether either still has a job to do. His orthostatic symptoms, on closer questioning, appeared around the same time as the new antihypertensive but have not clearly improved since that drug's own dose was reduced last week — raising the possibility that tamsulosin, not the new agent, is the actual driver. That timing detail matters: if the new antihypertensive alone were responsible, halving its dose should have produced at least a partial improvement, and it hasn't. He has no other significant medical history — no diabetes, no prior cardiac events — and until his cardiologist added the new antihypertensive, he had never had an orthostatic complaint in his life.
Revisiting two drugs nobody has looked at since surgery was scheduled
His symptom score dropped from severe to minimal after surgery, and he now has a real, ongoing adverse effect that started around the time both his new antihypertensive and, we should remember, his existing tamsulosin were both still active. The surgical indication is gone. I'd taper both drugs now.
I'd slow down on stopping both at once. Rieken and colleagues' systematic review of medical therapy after prostate surgery found alpha-blocker use still running anywhere from 8.7% to 57% of men at six months post-TURP, and persistent lower urinary tract symptoms in roughly 20% to 50% — a real minority have residual adenoma or bladder-neck dysfunction that only becomes apparent once medication is withdrawn. If we stop both together and symptoms come back, we won't know which drug's absence caused it — that's a genuine diagnostic cost even if it's the slower path.
And I'll grant the obvious point against me: at a symptom score of 4 he is squarely in the majority those figures leave out. I'm not arguing to continue an alpha-blocker that's causing him harm right now — I'm arguing for sequencing the two stops so we can actually learn something if symptoms return.
That sequencing question answers itself once you stop treating these as one "BPH regimen." Tamsulosin's original job — relieving obstruction from tissue that's now resected — has no remaining rationale, and it's also the more plausible cause of his orthostatic drop given its vascular alpha-1 activity. Stop that one now. Finasteride's original goal, shrinking a gland large enough to have warranted surgery in the first place, is arguably still relevant on its own terms regardless of what happened to the resected tissue — that's a separate question, decided separately, not resolved by what we do about the drug that's actually hurting him today.
Agreed: stop tamsulosin now given the resolved surgical indication and its likely contribution to his orthostatic symptoms; continue finasteride with a planned reassessment of whether it still has a role at six months.
Not agreed: whether finasteride's continuation should carry a firm stop date set today rather than an open-ended reassessment. The pharmacologist wants a fixed endpoint to prevent exactly the kind of never-revisited drift that produced this visit's problem; the urologist prefers case-by-case reassessment based on how he's doing.